GHK-Cu (GHK copper peptide) — what it does, evidence, and safety

What it is

GHK-cu is a small copper-bound peptide best known for research into skin, hair, and wound healing. It occurs naturally in the human body, where levels decline with age. Topical GHK-cu is legal as a cosmetic ingredient in the US, but it is not FDA-approved as a drug. Injectable GHK-cu sits in a regulatory gray area: its FDA compounding nomination was withdrawn, so it isn't on the approved compounding list, and a further regulatory review is expected within the next year.

What the research found

GHK-cu, a copper peptide, has been studied mainly for skin, collagen, and wound healing. Decades of topical and lab research link it to collagen production and skin appearance, and gene-expression studies document broad activity — but most of this is cellular or lab-based rather than controlled human trials, and a 2024 review noted a surprising absence of clinical studies even for topical anti-wrinkle use. The injectable use some people pursue is thinner still: two 2026 orthopedic reviews state no clinical data support GHK-cu for musculoskeletal conditions. The label below applies to the topical side; injectable use is preclinical and research-community reports only.

Status and regulatory position

Not FDA approved as a pharmaceutical drug for any indication. Topical GHK-cu is legal as a cosmetic active ingredient under FDA cosmetic regulation (no pre-approval required for cosmetic ingredients). Injectable GHK-cu: its 503A bulks-list nomination was WITHDRAWN, and FDA gave notice dated April 15, 2026 removing GHK-cu from its prior 503A category (effective on or about April 22, 2026). GHK-cu now sits in a transitional / regulatory gray area — it is not on the FDA 503A bulks list and not under formal enforcement discretion, with a PCAC consultation on GHK-cu planned before the end of February 2027. A withdrawn nomination is not permission to compound: compounding for injection still carries regulatory risk until FDA affirmatively lists the substance. Not listed in the WADA 2026 Prohibited List (confirmed by direct text-search of the canonical PDF on 2026-05-04; re-confirmed 2026-07-18). Currently sold as a research peptide in jurisdictions where this is permitted.

Safety

GHK-cu is not FDA-approved as a drug; topical use is legal as a cosmetic ingredient, while injectable GHK-cu is in a transitional regulatory position — its 503A compounding nomination was withdrawn in April 2026, it is not on the FDA 503A bulks list, and compounding for injection still carries regulatory risk. It is not named on the WADA Prohibited List, but being legal as a cosmetic ingredient is not the same as being approved as a medicine, and the injectable form has no such approval anywhere — WADA's S0 category prohibits exactly that by default, so treat injectable use as off-limits in drug-tested sport. VialWise is a research and educational reference, not medical advice — consult a licensed professional.

Disclosures

⚠️ For research and educational purposes only. GHK-cu is not approved by the FDA as a pharmaceutical drug for any indication. Information in this entry is informational, not medical advice. Always confirm dose calculations with the in-app calculator and consult appropriate professional guidance before any protocol decisions.

⚠️ Precision matters at low doses. GHK-cu is dosed in milligrams per dose, but typical research-community injectable doses ( per dose) at typical reconstitution concentrations produce small draws in the range on a U-100 syringe. At those draw sizes, even a one-unit error is a meaningful percentage of the dose (a one-unit error is ~33%; the same one-unit error is ~14%). Always verify draws against the in-app calculator and double-check the unit count on the syringe before injecting — most acutely at the smallest draws in your titration.

⚠️ Topical and injectable GHK-cu are pharmacologically and regulatorily distinct. Topical GHK-cu (cosmetic serums, creams, hair products) and injectable GHK-cu (subcutaneous research-community use) are not interchangeable. They have different pharmacokinetic profiles (topical absorption is limited; injectable bypasses the skin barrier entirely), different effective dose ranges (topical formulations are typically 0.05–2% w/v; injectable doses are absolute amounts in mg), and different regulatory contexts (topical is legal as a cosmetic ingredient under FDA cosmetic regulation; injectable GHK-cu's 503A bulks-list nomination was withdrawn in April 2026, leaving it off the 503A bulks list and in a transitional gray area — not affirmatively permitted for compounding). Most published clinical and preclinical efficacy data refers to topical or in-vitro formulations; injectable subcutaneous research-community use is supported by extrapolation from topical/in-vitro mechanism data plus accumulated researcher experience, not by RCTs on the injectable formulation. Researchers should be explicit with themselves about which formulation they are using and the regulatory context that applies.

⚠️ Note on regulatory framing. GHK-cu's regulatory profile is unusually layered for a research peptide. Four distinct regulatory categories apply, none of which constitute pharmaceutical drug approval: (1) FDA cosmetic ingredient — topical use is legal without pre-approval; (2) FDA 503A compounding — GHK-cu's bulks-list nomination was withdrawn, and an FDA notice dated April 15, 2026 removed it from its prior category; it is now in a transitional / gray-area status: not on the 503A bulks list, and not under formal enforcement discretion either, with a PCAC (Pharmacy Compounding Advisory Committee) consultation on GHK-cu planned before the end of February 2027. This is a separate track from the broader peptide PCAC meeting scheduled for July 23–24, 2026 (which covers other compounds); (3) WADA 2026 Prohibited List — GHK-cu is not listed (notable absence; injectable/systemic use could arguably be read into the S2.3 "other growth factors" catch-all, though WADA has not invoked it — researchers competing in WADA-tested sport should still confirm against the most recent edition before any competitive event); (4) EU and other jurisdictions vary. Some research-community marketing materials conflate FDA cosmetic-ingredient legality with pharmaceutical approval; the conflation is incorrect. This entry takes care to distinguish the categories rather than collapsing them.

Quick reference

Common vial sizes (injectable)	(research/compounded). Branded pharmaceutical injectable products do not exist.
Common topical concentrations	0.05%–2% w/v in serums, creams, and hair products. Cosmetic INCI name "Copper Tripeptide-1" or "Tripeptide-1."
Frequency	Daily, often pre-bed; some protocols 3–5 times per week rather than every day
Half-life	Short. Plasma half-life of free GHK is reported in the minutes-to-hours range; copper-bound GHK-cu pharmacokinetics for the injectable formulation are not well characterized in human studies.
Route	Topical (most common — cosmetic and hair applications); subcutaneous (research community injectable use); intramuscular reported but uncommon
Onset of action	Subjective skin/hair effects typically reported within 4–8 weeks of consistent use in research-community reports. Not validated in published human RCTs at injectable doses for non-cosmetic indications.

In depth

GHK-cu (glycyl-L-histidyl-L-lysine copper(II)) is a small endogenous tripeptide-copper complex that occurs naturally in human plasma and tissue. The peptide was first isolated and described by Loren Pickart in 1973 during studies of plasma factors that affected aging hepatocytes; subsequent work characterized the peptide's affinity for copper and its broad regenerative and protective biological activities.[¹] Unlike most peptides covered elsewhere in this library, GHK-cu is not a synthetic compound — it is naturally produced by the human body, with circulating plasma levels of approximately 200 ng/mL at age 20, declining to approximately 80 ng/mL by age 60.[¹][¹²] (This decline figure is reported independently of the originating research group,[¹²] which matters because most other mechanism claims in this entry trace to a single lab.) This age-related decline coincides with the broader observed decline in regenerative capacity and is one of the conceptual underpinnings of GHK-cu's research-community framing as an "anti-aging" or "regenerative" peptide.

Mechanism. GHK-cu's biological activity is unusually broad for a small peptide. Transcriptomic studies have documented modulation of expression of more than 4,000 human genes — approximately 31% of the gene set studied showed expression changes greater than or equal to 50%, with 59% of those genes upregulated and 41% downregulated.[²][³] Mechanistically, the copper-binding role is central: GHK forms a stable complex with copper(II) ions in which the redox activity of free copper is silenced, allowing nontoxic delivery of copper into cells. Copper is required by more than a dozen vital enzymes including those involved in connective tissue synthesis, antioxidant defense, and cellular respiration.[¹] Specific downstream effects documented in dermal fibroblast culture and in animal wound-healing models include: increased collagen (types I and III) and elastin synthesis, upregulation of TGF-β receptor expression, decreased matrix metalloproteinase 2 and 9 (MMP-2, MMP-9) activity, decreased TNF-β, increased glutathione (GSH) and ascorbic acid concentrations in healing tissue, and faster epithelialization in wound models.[¹][²][⁴]

Regulatory status. GHK-cu has never received FDA approval as a pharmaceutical drug for any indication. The compound holds legal cosmetic ingredient status in the US — topical formulations (serums, creams, hair products) at typical cosmetic concentrations (0.05%–2% w/v) are legal under FDA cosmetic regulation, which does not require pre-approval for cosmetic ingredients. The injectable picture changed materially in April 2026. Earlier versions of this entry described injectable GHK-cu as sitting on Category 2 of the FDA 503A bulks list — the designation that would have barred 503A pharmacies from compounding it for injection. That is no longer correct: GHK-cu's 503A nomination was withdrawn, and an FDA notice dated April 15, 2026 removed GHK-cu from its prior 503A category, effective on or about April 22, 2026.[⁵] The result is a transitional / regulatory gray area rather than a permission: GHK-cu is not on the FDA 503A bulks list, no longer carries the "significant safety risks" designation, and is not under formal enforcement discretion either. A PCAC (Pharmacy Compounding Advisory Committee) consultation on GHK-cu is planned before the end of February 2027 — a separate track from the broader peptide PCAC meeting set for July 23–24, 2026. Researchers should read this as a change in regulatory *category*, not as clearance: compounding GHK-cu for injection continues to carry regulatory risk until FDA affirmatively lists the substance. GHK-cu is not listed in the WADA 2026 Prohibited List (not named; injectable/systemic GHK-cu still has no therapeutic approval anywhere, so S0 captures it by default) — direct text-search of the canonical 2026 WADA pdf (downloaded and archived at `docs/legal/wada-2026-prohibited-list.pdf` on 2026-05-04) returned no matches for GHK, glycyl-histidyl, tripeptide-1, or copper peptide.[⁶] This is a notable absence — most healing and regenerative peptides covered elsewhere in this library (TB-500, BPC-157 derivatives, GH-secretagogues) are listed under WADA Section S2. Researchers competing in WADA-tested sport should still confirm against the most recent annual Prohibited List edition before any competitive event.

Common research interests. Despite the absence of pharmaceutical approval, GHK-cu is one of the most widely used regenerative peptides across both cosmetic and research-community contexts. Common areas of use include: - Skin (topical) — anti-aging serums, post-procedure recovery (laser, microneedling), wound healing adjunct, fine-line and firmness improvement - Hair (topical) — androgenetic alopecia and hair-thinning protocols, often as a 0.05–0.5% serum either alone or stacked with minoxidil/dutasteride - Wound and tissue repair (topical or injectable) — burn recovery, surgical site recovery, chronic wound management - Joint and connective tissue (injectable, research community) — research-community use parallel to BPC-157/TB-500 patterns; preclinical evidence base is thinner than for BPC-157 - General "anti-aging" / regenerative protocols — research-community injectable use as part of broader peptide stacks aimed at recovery and connective tissue support

These uses span clinically validated topical applications (where the cosmetic and dermatology literature is meaningful) and extrapolation-based injectable applications (where the evidence base is fundamentally preclinical/in-vitro). Researchers should be explicit with themselves about which use case applies and what the supporting evidence base looks like for that specific use.

Recent clinical interest in hair regrowth. Beginning in the late 2010s, GHK-cu has been studied as a topical adjunct to minoxidil for androgenetic alopecia. The best-locked recent citation is Kuceki et al. (2025), a *JAAD International* study of minoxidil-dutasteride-copper-peptide tattooing (MDCT) in androgenetic alopecia, in which participants received five monthly sessions and hair regrowth was assessed by artificial intelligence and by blinded evaluators.[⁷] Findings in that study are attributable to the combination delivery protocol, not to GHK-cu in isolation.

A note on a widely circulated figure that this entry does not carry. Research-community materials frequently reference a "2022 split-scalp study of 0.5% GHK-cu serum vs 3% minoxidil" reporting a specific percentage advantage for GHK-cu. A dedicated PubMed search on 2026-07-18 across multiple query variants returned no matching peer-reviewed publication. The specific figures previously carried in this entry have therefore been removed as unsourced, and researchers should treat any version of that claim they encounter elsewhere as unverified until a primary publication is produced. The published topical hair-regrowth evidence base is real but thinner than research-community summaries imply.

Reported side effects

Commonly reported

Injection site reactions (local redness, soreness, mild swelling)
Transient flushing or warmth in the minutes after injection (uncommon)
Mild nausea or dizziness reported rarely with injectable use
Headache (uncommon, typically transient)
No consistent pattern of serious adverse events in research-community reports, though no controlled long-term safety surveillance exists
Copper-related concerns at supraphysiologic systemic exposure — injectable GHK-cu delivers copper to circulation at doses orders of magnitude above endogenous plasma levels. Long-term effects on copper homeostasis, including potential interaction with conditions affecting copper metabolism (Wilson disease, Menkes disease), are not well-characterized in clinical data. This is the most commonly cited theoretical safety issue specific to the injectable formulation.
Long-term safety in humans for the injectable formulation is essentially unknown. No multi-year human safety dataset exists for the subcutaneous research-community use pattern. The topical safety data does not directly transfer to the injectable formulation.
Allergic / hypersensitivity reactions — copper-sensitive individuals can experience local or systemic reactions. Patch testing is recommended for first-time topical users with known metal sensitivities.

Contraindications and warnings

Wilson disease (or other disorders of copper metabolism) — strongly contraindicated. Wilson disease patients accumulate copper pathologically; adding exogenous copper via GHK-cu is contraindicated regardless of formulation.

Active copper supplementation — caution; risk of copper accumulation if combined with high-dose oral copper supplementation

Pregnancy and lactation: no data; default to contraindicated — no published reproductive toxicology in humans for either topical or injectable formulations

Pediatric use: no data — should not be used in researchers under 18

Active anti-coagulation, immunosuppressive, or chemotherapeutic regimens — no published interaction data for the injectable formulation

Active malignancy or undiagnosed cancer concern — theoretical contraindication driven by GHK-cu's broad gene-expression-modulating activity. The published literature is mixed: some studies report anti-cancer activity in tumor models, while others raise the question of tumor-supporting effects; no definitive human safety data exists.[⁴]

Known copper allergy or metal sensitivity — contraindicated for both topical and injectable use

Regulatory note (US, injectable specifically): As of this entry's last-updated date, injectable GHK-cu is not on the FDA 503A bulks list — its nomination was withdrawn and an FDA notice dated April 15, 2026 removed it from its prior category, leaving a transitional / gray-area status that is neither a prohibition nor a clearance, with PCAC consultation planned before the end of February 2027.[⁵] Compounding for injection still carries regulatory risk until FDA affirmatively lists the substance; researchers should be aware of the regulatory environment in their jurisdiction.

Regulatory note (WADA): GHK-cu is not listed in the 2026 WADA Prohibited List. Not-named is not not-prohibited, and cosmetic legality is not therapeutic approval: FDA cosmetic ingredients require no pre-approval at all, so topical legality is not "approval by a governmental regulatory health authority for human therapeutic use". Injectable/systemic GHK-cu holds no such approval anywhere, so WADA's S0 (Non-Approved Substances) captures it by default and it is off-limits in drug-tested sport. (Topical cosmetic use is a separate question S0 does not cleanly reach.) Verified against the local archive `docs/legal/wada-2026-prohibited-list.txt` on 2026-09-07.[⁶] This may change in future annual editions; researchers competing in WADA-tested sport should confirm against the most recent edition before any competitive event.

Key terms

Peptide: A short chain of amino acids, the building blocks of proteins. Many compounds in this library are peptides.
Topical: applied to the skin (as a cream or serum) rather than injected.
Subcutaneous: An injection into the fatty layer just under the skin, rather than into a muscle or vein.
Compounding pharmacy: a pharmacy that prepares a medication to order under a prescription.

Sources

Related entries

BPC-157 / TB-500 Blend — discussed together in this entry's stacks section
CJC-1295 / Ipamorelin Blend — discussed together in this entry's stacks section
ARA-290 — same mechanism class
BPC-157 — same mechanism class
GLOW — same mechanism class
KLOW — same mechanism class